Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 3, 2016, Pages 438-448

  Candido, Saverio ^a   Abrams, Stephen L ^b   Steelman, Linda S ^b   Lertpiriyapong, Kvin ^b   Fitzgerald, Timothy L ^b   Martelli, Alberto M ^c   Cocco, Lucio ^c   Montalto, Giuseppe ^d,e   Cervello, Melchiorre ^e   Polesel, Jerry ^f   Libra, Massimo ^a   McCubrey, James A ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b EAST CAROLINA UNIVERSITY   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e CNR   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Drug resistance; Iron transport; Lcn2; Lipocalins; MMP 9; NGAL; Siderocalins

Indexed keywords

BERBERINE; BIOLOGICAL MARKER; DEFEROXAMINE; DOXORUBICIN; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PACLITAXEL; RAPAMYCIN; ACUTE PHASE PROTEIN; ANTINEOPLASTIC AGENT; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; PROTEIN BINDING;

BACTERIAL INFECTION; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL HYPOXIA; CELL SURVIVAL; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; IRON STORAGE; IRON TRANSPORT; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY;

ACUTE-PHASE PROTEINS; ANTINEOPLASTIC AGENTS; HUMANS; LIPOCALINS; MATRIX METALLOPROTEINASE 9; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84955200962     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.08.010     Document Type: Review

References (159)

1. Flower D.R. The lipocalin protein family: structure and function. Biochem. J. 1996, 318:1-14.
2. Kjeldsen L., Johnsen A., Sengeløv H., Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993, 268:10425-10432.
3. Bolignano D., Donato V., Coppolino G., Campo S., Buemi A., Lacquaniti A., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am. J. Kidney Dis. 2008, 52:595-605.
4. Yan L., Borregaard N., Kjeldsen L., Moses MA M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 2001, 276:37258-37265.
5. Fernández C.A., Yan L., Louis G., Yang J., Kutok J.L., Moses M.A. The matrix metalloproteinase-9/neutrophil gelatin associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. 2005, 11:5390-5395.
6. Kubben F.J., Sier C.F., Hawinkels L.J., Tschesche H., van Duijn W., Zuidwijk K., van der Reijden J.J., Hanemaaijer R., Griffioen G., Lamers C.B., Verspaget H.W. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur. J. Cancer 2007, 43:1869-1876.
7. Zhang H., Xu L., Xiao D., Xie J., Zeng H., Wang Z., Zhang X., Niu Y., Shen Z., Shen J., Wu X., Li E. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J. Clin. Pathol. 2007, 60:555-561.
8. Ebrahimi T., Pirasteh H., Rezakhaniha B., Dormanesh B., Rabati R.G., Yahaghi E., Mokarizadeh A. The value of U-NGAL expression as a potential prognostic biomarker in patients with renal cancer after neoadjuvant chemotherapy with cisplatin. Tumour Biol. 2015, (in press).
9. Candido S., Maestro R., Polesel J., Catania A., Maira F., Signorelli S.S., McCubrey J.A., Libra M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget 2014, 5:1576-1594.
10. Leng X., Wu Y., Arlinghaus R.B. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J. Cell. Physiol. 2011, 226:309-314.
11. Rodvold J.J., Mahadevan N.R., Zanetti M. Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett. 2012, 316:132-138.
12. Tschesche H., Zölzer V., Triebel S., Bartsch S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur. J. Biochem. 1918-1928, 268(2001).
13. Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., Strong R.S. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore mediated iron acquisition. Mol. Cell 2002, 10:1033-1043.
14. Rapoport D., Drexler I.R., Foster K., Yang J., Schmidt-Ott K.M., Chen X., Li J.Y., Weiss S., Mishra J., Cheema F.H., Markowitz G., Suganami T., Sawai K., Mukoyama M., Kunis C., D'Agati V., Devarajan P., Barasch J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 2005, 115:610-621.
15. Bao G., Clifton M., Hoette T.M., Mori K., Deng S.X., Qiu A., Viltard M., Williams D., Paragas N., Leete T., Kulkarni R., Li X., Lee B., Kalandadze A., Ratner A.J., Pizarro J.C., Schmidt-Ott K.M., Landry D.W., Raymond K.N., Strong R.K., Barasch J. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat. Chem. Biol. 2010, 6:602-609.
16. Coudevylle N., Geist L., Hötzinger M., Hartl M., Kontaxis G., Bister K., Konrat R. The v-myc-induced Q83 lipocalin is a siderocalin. J. Biol. Chem. 2010, 285:41646-42652.
17. Coudevylle N., Hoetzinger M., Geist L., Kontaxis G., Hartl M., Bister K., Konrat R. Lipocalin Q83 reveals a dual ligand binding mode with potential implications for the functions of siderocalins. Biochemistry 2011, 50:9192-9199.
18. Torti S.V., Torti FM F.M. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 2013, 13:342-355.
19. Bellmann-Weiler R., Schroll A., Engl S., Nairz M., Talasz H., Seifert M., Weiss G. Neutrophil gelatinase-associated lipocalin and interleukin-10 regulate intramacrophage Chlamydia pneumoniae replication by modulating intracellular iron homeostasis. Immunobiology 2013, 218:969-978.
20. Yu Y., Kovacevic Z., Richardson DR D.R. Tuning cell cycle regulation with an iron key. Cell Cycle 2007, 6:1982-1994.
21. Le N.T., Richardson D.R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004, 104:2967-2975.
22. Kovacevic Z., Richardson D.R. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006, 27:2355-2366.
23. Kovacevic Z., Fu D., Richardson D.R. The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim. Biophys. Acta 2008, 1783:1981-1992.
24. Kovacevic Z., Chikhani S., Lui G.Y., Sivagurunathan S., Richardson D.R. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid. Redox Signal. 2013, 18:874-887.
25. Yu Y., Gutierrez E., Kovacevic Z., Saletta F., Obeidy P., Suryo Rahmanto Y., Richardson D.R. Iron chelators for the treatment of cancer. Curr. Med. Chem. 2012, 19:2689-2702.
26. Buss J.L., Greene B.T., Turner J., Torti F.M., Torti S.V. Iron chelators in cancer chemotherapy. Curr. Top. Med. Chem. 2004, 4:1623-1635.
27. Harrison L.B., Chadha M., Hill R.J., Hu K., Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7:492-508.
28. Sarafanov A.G., Todorov T.I., Centeno J.A., Macias V., Gao W., Liang W.M., Beam C., Gray M.A., Kajdacsy-Balla A.A. Prostate cancer outcome and tissue levels of metal ions. Prostate 2011, 71:1231-1238.
29. Pavlides S., Tsirigos A., Migneco G., Whitaker-Menezes D., Chiavarina B., Flomenberg N., Frank P.G., Casimiro M.C., Wang C., Pestell R.G., Martinez-Outschoorn U.E., Howell A., Sotgia F., Lisanti M.P. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010, 17:3485-3505.
30. Brazzolotto X., Andriollo M., Guiraud P., Favier A., Moulis J.M. Interactions between doxorubicin and the human iron regulatory system. Biochim. Biophys. Acta 2003, 1593:209-218.
31. Davies N.P., Suryo Rahmanto Y., Chitambar C.R., Richardson D.R. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J. Pharmacol. Exp. Ther. 2006, 317:153-162.
32. Whitnall M., Howard J., Ponka P., Richardson DR D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14901-14906.
33. Ganguly A., Chakraborty P., Banerjee K., Chatterjee S., Basu S., Sarkar A., Chatterjee M., Choudhuri S.K. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. BioMetals 2012, 25:149-163.
34. Yang J., Goetz D., Li J.Y., Wang W., Mori K., Setlik D., Du T., Erdjument-Bromage H., Tempst P., Strong R., Barasch J. An iron delivery pathway mediated by a lipocalin. Mol. Cell 2002, 10:1045-1056.
35. Devireddy L.R., Gazin C., Zhu X., Green M.R. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005, 123:1293-1305.
36. Harada H., Quearry B., Ruiz-Vela A., Korsmeyer S.J. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15313-15317.
37. Shinjyo T., Kuribara R., Inukai T., Hosoi H., Kinoshita T., Miyajima A., Houghton P.J., Look A.T., Ozawa K., Inaba T. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol. Cell. Biol. 2001, 21:854-864.
38. Kuribara R., Honda H., Matsui H., Shinjyo T., Inukai T., Sugita K., Nakazawa S., Hirai H., Ozawa K., Inaba T. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol. Cell. Biol. 2004, 24:6172-6183.
39. Devireddy L.R., Teodoro J.G., Richard F.A., Green M.R. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001, 293:829-834.
40. Chakraborty S., Kaur S., Guha S., Batra S.K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta 2012, 1826:129-169.
41. Mori K., Suzuki T., Minamishima S., Igarashi T., Inoue K., Nishimura D., Seki H., Yamada T., Kosugi S., Katori N., Hashiguchi S., Morisaki H. Neutrophil gelatinase-associated lipocalin regulates gut microbiota of mice. J. Gastroenterol. Hepatol. 2015, 204:471-479.
42. Nasioudis D., Witkin S.S. Neutrophil gelatinase-associated lipocalin and innate immune responses to bacterial infections. Med. Microbiol. Immunol. 2015, 204:471-479.
43. Miao Q., Ku A.T., Nishino Y., Howard J.M., Rao A.S., Shaver T.M., Garcia G.E., Le D.N., Karlin K.L., Westbrook T.F., Poli V., Nguyen H. Tcf3 promotes cell migration and wound repair through regulation of lipocalin 2. Nat. Commun. 2014, 5:4088.
44. Bahmani B., Roudkenar M.H., Halabian R., Jahanian-Najafabadi A., Amiri F., Jalili M.A. Lipocalin 2 decreases senescence of bone marrow-derived mesenchymal stem cells under sub-lethal doses of oxidative stress. Cell Stress Chaperones 2014, 19:685-693.
45. Ramirez-Sandoval J.C., Herrington W., Morales-Buenrostro L.E. Neutrophil gelatinase-associated lipocalin in kidney transplantation: a review. Transplant. Rev. 2015, 29:139-144.
46. Jha M.K., Lee S., Park D.H., Kook H., Park K.G., Lee I.K., Suk K. Diverse functional roles of lipocalin-2 in the central nervous system. Neurosci. Biobehav. Rev. 2015, 49:135-156.
47. Ferreira A.C., Dá Mesquita S., Sousa J.C., Correia-Neves M., Sousa N., Palha J.A., Marques F. From the periphery to the brain: lipocalin-2, a friend or foe?. Prog. Neurobiol. 2015, 131:120-136.
48. Boca S., Koestler F., Ksas B., Chevalier A., Leymarie J., Fekete A., Mueller M.J., Havaux M. Arabidopsis lipocalins AtCHL and AtTIL have distinct but overlapping functions essential for lipid protection and seed longevity. Plant Cell Environ. 2014, 37:368-381.
49. Cowland J.B., Sørensen O.E., Sehested M., Borregaard N. Neutrophil gelatinase-associated lipocalin is up regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J. Immunol. 2003, 171:6630-6639.
50. Cowland J.B., Muta T., Borregaard N. IL-1beta-specific upregulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J. Immunol. 2006, 176:5559-5566.
51. Karlsen J.R., Borregaard N., Cowland J.B. Induction of neutrophil gelatinase-associated lipocalin expression by costimulation with interleukin-17 and tumor necrosis factor alpha is controlled by IkappaB-zeta but neither by C/EBPbeta nor C/EBP-delta. J. Biol. Chem. 2010, 285:14088-14100.
52. Kohda A., Yamazaki S., Sumimoto H. DNA element downstream of the κB site in the Lcn2 promoter is required for transcriptional activation by IκBζ and NF-κB p50. Genes Cells 2014, 19:620-628.
53. Li S.H., Hawthorne V.S., Neal C.L., Sanghera S., Xu J., Yang J., Guo H., Steeg P.S., Yu D. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Res. 2009, 69:9163-9168.
54. Martelli A.M., Lonetti A., Buontempo F., Ricci F., Tazzari P.L., Evangelisti C., Bressanin D., Cappellini A., Orsini E., Chiarini F. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. Adv. Biol. Regul. 2014, 56:6-21.
55. McCubrey J.A., Davis N.M., Abrams SL S.L., Montalto G., Cervello M., Libra M., Nicoletti F., D'Assoro A.B., Cocco L., Martelli A.M., Steelman L.S. Targeting breast cancer initiating cells: advances in breast cancer research and therapy. Adv Biol Regul 2014, 56:81-107.
56. Simioni C., Cani A., Martelli A.M., Zauli G., Alameen A.A., Ultimo S., Tabellini G., McCubrey J.A., Capitani S., Neri L.M. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 2015, 6:17147-17160.
57. Fragoso R., Barata J.T. PTEN and leukemia stem cells. Adv Biol Regul 2014, 56:22-29.
58. Toker A., Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul 2014, 55:28-38.
59. Chiarini F., Evangelisti F,.C., McCubrey J.A., Martelli A.M. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol. Sci. 2015, 36:124-135.
60. McCubrey J.A., Davis N.M., Abrams S.L., Montalto G., Cervello M., Basecke J., Libra M., Nicoletti F., Cocco L., Martelli A.M., Steelman L.S. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul 2014, 54:176-196.
61. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Abrams S.L., Montalto G., D'Assoro A.B., Libra M., Nicoletti F., Maestro R., Basecke J., Cocco L., Cervello M., Martelli A.M. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2014, 28:15-33.
62. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Montalto G., Cervello M., Nicoletti F., Fagone P., Malaponte G., Mazzarino M.C., Candido S., Libra M., Bäsecke J., Mijatovic S., Maksimovic-Ivanic D., Milella M., Tafuri A., Cocco L., Evangelisti C., Chiarini F., Martelli A.M. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012, 3:954-987.
63. Ribeiro D., Melão A., Barata J.T. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. Adv Biol Regul 2013, 53:211-222.
64. Dorritie K.A., Redner R.L., Johnson D.E. STAT transcription factors in normal and cancer stem cells. Adv Biol Regul 2014, 56:30-44.
65. Barre B., Coqueret O., Perkins N.D. Regulation of activity and function of the p52 NF-kappaB subunit following DNA damage. Cell Cycle 2010, 9:4795-4804.
66. Melvin A., Mudie S., Rocha S. Further insights into the mechanism of hypoxia-induced NFkappaB. Cell Cycle 2011, 10:879-882.
67. Matsuo S., Yamazaki S., Takeshige K., Muta T. Crucial roles of binding sites for NF-kappaB and C/EBP in IkappaB-zeta-mediated transcriptional activation. Biochem. J. 2007, 405:605-615.
68. Iannetti A., Pacifico F., Acquaviva R., Lavorgna A., Crescenzi E., Vascotto C., Tell G., Salzano A.M., Scaloni A., Vuttariello E., Chiappetta G., Formisano S., Leonardi A. The neutrophils gelatinase-associated lipocalin (NGAL) a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14058-14063.
69. Mir S.U., Jin L., Craven R.J. Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J. Biol. Chem. 2012, 287:14494-14501.
70. Xu M.J., Feng D., Wu H., Wang H., Chan Y., Kolls J., Borregaard N., Porse B., Berger T., Mak T.W., Cowland J.B., Kong X., Gao B. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology 2015, 61:692-702.
71. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F., Langdon S.P. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol. Oncol. 2007, 106:461-468.
72. Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., Gould M.N. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int. J. Cancer 1998, 79:565-572.
73. Bauer M., Eickhoff J.C., Gould M.N., Mundhenke C., Maass N., Friendl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res. Treat. 2008, 108:389-397.
74. Wenners A.S., Mehta K., Loibl S., Park H., Mueller B., Arnold N., Hamann S., Weimer J., Ataseven B., Darb-Esfahani S., Schem C., Mundhenke C., Khandan F., Thomssen C., Jonat W., Holzhausen H.J., von Minckwitz G., Denkert C., Bauer M. Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer. PLoS One 2012, 7:e45826.
75. Nadendla S.K., Hazan A., Ward M., Harper L.J., Moutasim K., Bianchi L.S., Naase M., Ghali L., Thomas G.J., Prowse D.M., Philpott M.P., Neill G.W. GLI1 confers profound phenotypic changes upon LNCaP prostate cancer cells that include the acquisition of a hormone independent state. PLoS One 2011, 6:e20271.
76. Mahadevan N.R., Rodvold J., Almanza G., Pérez A.F., Wheeler M.C., Zanetti M. ER stress drives lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. BMC Cancer 2011, 11:229.
77. Drew B.G., Hamidi H., Zhou Z., Villanueva C.J., Krum S.A., Calkin A.C., Parks B.W., Ribas V., Kalajian N.Y., Phun J., Daraei P., Christofk H.R., Hewitt S.C., Korach K.S., Tontonoz P., Lusis A.J., Slamon D.J., Hurvitz S.A., Hevener A.L. Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. J. Biol. Chem. 2015, 290:5566-5581.
78. Maier H.T., Aigner F., Trenkwalder B., Zitt M., Vallant N., Perathoner A., Margreiter C., Moser P., Pratschke J., Amberger A. Up-regulation of neutrophil gelatinase-associated lipocalin in colorectal cancer predicts poor patient survival. World J. Surg. 2014, 38:2160-2167.
79. Duvillard L., Ortega-Deballon P., Bourredjem A., Scherrer M.L., Mantion G., Delhorme J.B., Deguelte-Lardière S., Petit J.M., Bonithon-Kopp C., AGARIC study group A case-control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer. BMC Cancer 2014, 14:912.
80. Srdelić Mihalj S., Kuzmić-Prusac I., Zekić-Tomaš S., Šamija-Projić I., Čapkun V. Lipocalin-2 and matrix metalloproteinase-9 expression in high-grade endometrial cancer and their prognostic value. Histopathology 2015, 67:206-215.
81. Du Z.P., Wu B.L., Xie Y.M., Zhang Y.L., Liao L.D., Zhou F., Xie J.J., Zeng F.M., Xu X.E., Fang W.K., Li E.M., Xu L.Y. Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop. Biochim. Biophys. Acta 2015, 1853:2240-2250.
82. Chung I.H., Chen C.Y., Lin Y.H., Chi H.C., Huang Y.H., Tai P.J., Liao C.J., Tsai C.Y., Lin SL S.L., Wu M.H., Chen C.Y., Lin KH K.H. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer. Oncotarget 2015, 6:15050-15064.
83. Zhang Y., Fan Y., Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012, 36:294-299.
84. Wang Y.P., Yu G.R., Lee M.J., Lee S.Y., Chu I.S., Leem SH S.H., Kim D.G. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Hepatology 2013, 58:1349-1361.
85. Shiiba M., Saito K., Fushimi K., Ishigami T., Shinozuka K., Nakashima D., Kouzu Y., Koike H., Kasamatsu A., Sakamoto Y., Ogawara K., Uzawa K., Takiguchi Y., Tanzawa H. Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells. Int. J. Oncol. 2013 Apr, 42(4):1197-1204. 10.3892/ijo.2013.1815.
86. Tang J., Li J., Li S., Li J., Yu C., Wei C. Effect of inhibiting NGAL gene expression on A549 lung cancer cell migration and invasion. Zhongguo Fei Ai Za Zhi 2015 Apr, 18(4):187-192. 10.3779/j.issn.1009-3419.2015.04.03.
87. Ruiz-Morales J.M., Dorantes-Heredia R., Arrieta O., Chávez-Tapia N.C., Motola-Kuba D. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in lung adenocarcinoma. Tumour Biol. 2015 May, 36(5):3601-3610.
88. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., Thompson E.W., Quinn M.A., Rice G.E. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelial-mesenchymal transition. Int. J. Cancer 2007, 120:2426-2434.
89. Tong Z., Kunnumakkara A.B., Wang H., Matsuo Y., Diagaradjane P., Harikumar K.B., Ramachandran V., Sung B., Chakraborty A., Bresalier R.S., Logsdon C., Aggarwal B.B., Krishnan S., Guha S. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008, 68:6100-6108.
90. Moniaux N., Chakraborty S., Yalniz M., Gonzalez J., Shostrom V.K., Standop J., Lele S.M., Ouellette M., Pour P.M., Sasson AR A.R., Brand RE R.E., Hollingsworth M.A., Jain M., Batra S.K. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br. J. Cancer 2008, 98:1540-1547.
91. Tung M.C., Hsieh S.C., Yang S.F., Cheng C.W., Tsai R.T., Wang S.C., Huang M.H., Hsieh Y.H. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells. Prostate 2013, 73:1281-1290.
92. Zhang M., Zhao X., Deng Y., Tang B., Sun Q., Zhang Q., Chen W., Yao D., Yang J., Cao L., Guo H. Neutrophil gelatinase-associated lipocalin is an independent predictor of poor prognosis in papillary renal cell carcinoma. J. Urol. 2015, 194:647-652.
93. Friedl A., Stoesz S.P., Buckley P., Gould M.N. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues, cell type-specific pattern of expression. Histochem. J. 1999, 31:433-441.
94. Yang J., McNeish B., Butterfield C., Moses M.A. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. 2013, 27:45-50.
95. Bolignano D., Donato V., Lacquaniti A., Fazio M.R., Bono C., Coppolino G., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2010, 288:10-16.
96. Yang J., Bielenberg D.R., Rodig S.J., Doiron R., Clifton M.C., Kung A.L., Strong R.K., Zurakowski D., Moses M.A. Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3913-3918.
97. Leng X., Ding T., Lin H., Wang Y., Hu L., Hu J., Feig B., Zhang W., Puszai L., Symmans W.F., Wu Y., Arlinghaus R.B. Inhibition of lipocalin 2 impairs breast tumorigensis and metastasis. Cancer Res. 2009, 69:8579-8584.
98. Hu J., Van den Steen P.E., Sang Q.-X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 2007, 6:480-498.
99. Bourguignon L.Y., Gunja-Smith Z., Iida N., Zhu H.B., Young L.J., Muller W.J., Cardiff R.D. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast. J. Cell. Physiol. 1998, 176:206-215.
100. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999, 13:35-48.
101. Abecassis I., Olofsson B., Schmid M., Zaleman G., Kariguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp. Cell Res. 2003, 291:363-376.
102. Hu L., Hittelman W., Lu T., Ji P., Arlinghaus R., Shmulevich I., Hamilton S.R., Zhang W. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab. Investig. 2009, 89:531-548.
103. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
104. Venkatesha S., Hanai J., Seth P., Karumanchi S.A., Sukhatme V.P. Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol. Cancer Res. 2006, 4:821-829.
105. Provatopoulou X., Gounaris A., Kalogera E., Zagouri F., Flessas I., Goussetis E., Nonni A., Papassotiriou I., Zografos G. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009, 9:390.
106. Chappell W.H., Abrams S.L., Stadelman K.M., LaHair M.M., Franklin R.A., Cocco L., Evangelisti C., Chiarini F., Martelli A.M., Steelman L.S., McCubrey J.A. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Adv Biol Regul 2013, 53:146-155.
107. Bertrand F.E., McCubrey J.A., Angus C.W., Nutter J.M., Sigounas G. NOTCH and PTEN in prostate cancer. Adv Biol Regul 2014, 56:51-65.
108. Simioni C., Cani A., Martelli A.M., Zauli G., Tabellini G., McCubrey J., Capitani S., Neri L.M. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget 2014, 5:10034-10047.
109. Jhanwar-Uniyal M., Jeevan D., Neil J., Shannon C., Albert L., Murali R. Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. Adv Biol Regul 2013, 53:202-210.
110. Davis N.M., Sokolosky M., Stadelman K., Abrams S.L., Libra M., Candido S., Nicoletti F., Polesel J., Maestro R., D'Assoro A., Drobot L., Rakus D., Gizak A., Laidler P., Dulińska-Litewka J., Basecke J., Mijatovic S., Maksimovic-Ivanic D., Montalto G., Cervello M., Fitzgerald T.L., Demidenko Z., Martelli A.M., Cocco L., Steelman L.S., McCubrey J.A. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 2014, 5:4603-4650.
111. Chan J.J., Katan M. PLCε and the RASSF family in tumour suppression and other functions. Adv Biol Regul 2013, 53:258-279.
112. Chan J.J., Flatters D., Rodrigues-Lima F., Yan J., Thalassinos K., Katan M. Comparative analysis of interactions of RASSF1-10. Adv Biol Regul 2013, 53:190-201.
113. Fitzgerald T.L., McCubrey J.A. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv Biol Regul 2014, 56:45-50.
114. Chun J., Lee C., Hwang S.W., Im J.P., Kim J.S. Ursolic acid inhibits nuclear factor-κB signaling in intestinal epithelial cells and macrophages, and attenuates experimental colitis in mice. Life Sci. 2014, 110:23-34.
115. Zhao Z.J., Xiang J.Y., Liu L., Huang XL X.L., Gan H.T. Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates dextran sulfate sodium-induced colitis in mice. Int. Immunopharmacol. 2012, 12:169-174.
116. Nakajima H., Fujiwara H., Furuichi Y., Tanaka K., Shimbara N. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem. Biophys. Res. Commun. 2008, 328:1007-1013.
117. Ukaji T., Umezawa K. Novel approaches to target NF-κB and other signaling pathways in cancer stem cells. Adv Biol Regul 2014, 56:108-115.
118. Chappell W.H., Abrams S.L., Franklin R.A., Lahair M.M., Montalto G., Cervello M., Martelli A.M., Nicoletti F., Candido S., Libra M., Polesel J., Polesel J., Talamini R., Milella M., Tafuri A., Steelman L.S., McCubrey J.A. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle 2012, 11:4447-4461.
119. Chappell W.H., Abrams S.L., Montano G., Cervello M., Martelli A.M., Candido S., Libra M., Polesel J., Talamini R., Arlinghaus R., Steelman L.S., McCubrey J.A. Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget 2012, 3:1236-1245.
120. Salzano M., Rusciano M.R., Russo E., Bifulco M., Postiglione L., Vitale M. Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. Cell Cycle 2012, 11:2100-2106.
121. Howe C.J., LaHair M.M., Maxwell J.A., Lee J.T., Robinson P.J., Rodriguez-Mora O., McCubrey J.A., Franklin R.A. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J. Biol. Chem. 2002, 277:30469-30476.
122. Jensen T.E., Rose A.J., Jørgensen S.B., Brandt N., Schjerling P., Wojtaszewski J.F., Richter E.A. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am. J. Physiol. Endocrinol. Metab. 2007, 292:1308-1317.
123. Franklin R.A., Rodriguez-Mora O.G., Lahair M.M., McCubrey J.A. Activation of the calcium/calmodulin dependent protein kinases as a consequence of oxidative stress. Antioxid. Redox Signal. 2006, 8:1807-1817.
124. Rodriguez-Mora O.G., Lahair M.M., Evans M.J., Kovacs C.J., Allison R.R., Sibata C.H., White K.S., McCubrey J.A., McCubrey J.A., Franklin R.A. Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol. Ther. 2006, 5:1022-1030.
125. Rodriquez-Mora O.G., LaHair M.M., McCubrey J.A., Franklin R.A. CaM-KI and CAM-KK participate in the control of cell cycle progression in MCF-7 breast cancer cells. Cancer Res. 2005, 65:5408-5416.
126. Liu B., Wang G., Yang J., Pan X., Yang Z., Zang L. Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLoS One 2011, 6:e21416.
127. Smith E.R., Zurakowski D., Saad A., Scott R.M., Moses MA M.A. Urinary biomarkers predict brain tumor presence and response to therapy. Clin. Cancer Res. 2008, 14:2378-2386.
128. Reilly P.T., Teo W.L., Low M.J., Amoyo-Brion A.A., Dominguez-Brauer C., Elia A.J., Berger T., Greicius G., Pettersson S., Mak T.W. Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression. Oncogene 2013, 32:1233-1239.
129. Berger T., Togawa A., Duncan G.S., Elia A.J., You-Ten A., Wakeham A., Fong H.E., Cheung C.C., Mak T.W. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1834-1839.
130. Viau A., El Karoui K., Laouari D., Burtin M., Nguyen C., Mori K., Pillebout E., Berger T., Mak T.W., Knebelmann B., Friedlander G., Barasch J., Terzi F. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J. Clin. Invest. 2010, 20:4065-4076.
131. Roy R., Lousi G., Loughlin K.R., Wiederschain D., Kilroy S.M., Lamb C.C., Zurakowski D., Moses M.D. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 2008, 14:6610-6617.
132. Catalan V., Gomez-Ambrosi J., Rodriguez A., Ramirez B., Silva C., Rotellar F., Hernandez-Lizoain J.L., Baixauli J., Valenti V., Pardo F., Salvador J., Fruhbeck G. Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J. Nutr. Biochem. 2011, 22:634-641.
133. Yazdani M., Merrikhi A., Beni Z.N., Baradaran A., Soleimani N., Musazade H. Association between neutrophil geletinase-associated lipocalin and iron deficiency anemia in children on chronic dialysis. J. Res. Med. Sci. Jul 2014, 19(7):624-628.
134. Ding G., Fang J., Tong S., Qu L., Jiang H., Ding Q., Liu J. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer. Prostate 2015, 75:957-968.
135. Shen F., Hu Z., Goswami J., Gaffen S.L. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 2006, 281:24138-24148.
136. Roukenar M.H., Kuwahara Y., Baba T., Roushandeh A.M., Ebishima S., Abe S., Ohkubo Y., Fukumoto M. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J. Radiat. Res. 2007, 48:39-44.
137. Zang X., Zheng F., Hong H.J., Jiang Y., Song Y., Xia Y. Neutrophil gelatinase-associated lipocalin protects renal tubular epithelial cells in hypoxia-reperfusion by reducing apoptosis. Int. Urol. Nephrol. 2014, 46:1673-1679.
138. Mellor A., Boos C., Stacey M., Hooper T., Smith C., Begley J., Yarker J., Piper R., O'Hara J., King R., Turner S., Woods D.R. Neutrophil gelatinase-associated lipocalin: its response to hypoxia and association with acute mountain sickness. Dis. Markers 2013, 355:37-42.
139. Cui C.Y., Yang S., Zhang J. Protective effects of neutrophil gelatinase-associated lipocalin on hypoxia/reoxygenation injury of HK-2 cells. Transplant. Proc. 2011, 43:3622-3627.
140. Xiong H., Luo T., He W., Xi D., Lu H., Li M., Liu J., Guo Z. Up-regulation of miR-138 inhibits hypoxia-induced cardiomyocyte apoptosis via down-regulating lipocalin-2 expression. Exp. Biol. Med. 2015, (in press).
141. Yu H., Zhou Q., Huang R., Yuan M., Ao X., Yang J. Effect of Cordyceps sinensis on the expression of HIF-1α and NGAL in rats with renal ischemia-reperfusion injury. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2012, 37:57-66.
142. Kobara H., Miyamoto T., Suzuki A., Asaka R., Yamada Y., Ishikawa K., Kikuchi N., Ohira S., Shiozawa T. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia. Placenta Nov 2013, 34(11):1036-1043. (Epub 2013 Aug 20). 10.1016/j.placenta.2013.08.004.
143. Halabian R., Tehrani H.A., Jahanian-Najafabadi A., Habibi Roudkenar M. Lipocalin-2-mediated upregulation of various antioxidants and growth factors protects bone marrow-derived mesenchymal stem cells against unfavorable microenvironments. Cell Stress Chaperones 2013, 18:785-800.
144. Sickinger S., Maier H., Konig S., Vallant N., Kofler M., Schumpp P., Schwelberger H., Hermann M., Obrist P., Schneeberger S., Margreiter R., Troppmair J., Pratschke J., Aigner F. Lipocalin-2 as mediator of chemokine expression and granulocyte infiltration during ischemia and reperfusion. Transpl. Int. 2013, 26:761-769.
145. Cui L.Y. S Yang, J. Zhang, Protective effects of neutrophil gelatinase-associated lipocalin on hypoxia/reoxygenation injury of HK-2 cells. Transplant. Proc. 2011, 43:3622-3627.
146. Yang J., Moses M.A. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009, 8:2347-2352.
147. Deryugina E.I., Zajac E., Juncker-Jensen A., Kupriyanova T.A., Welter L., Quigley J.P. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia 2014, 16:771-788.
148. Wani N., Nasser N.W., Ahirwar D.K., Zhao H., Miao Z., Shilo K., Ganju R.X. C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res. 2014, 16:R54.
149. Wang Y., Wu H., Wu X., Bian Z., Gao Q. Interleukin 17A promotes gastric cancer invasiveness via NF-kappaB mediated matrix metalloproteinases 2 and 9 expression. PLoS ONE 2014, 9:e96678.
150. Voura E.B., English J.L., Yu H.Y., Ho A.T., Subarsky P., Hill R.P., Hojilla C.V., Khokha R. Proteolysis during tumor cell extravasation in vitro: metalloproteinase involvement across tumor cell types. PLoS ONE 2013, 8:e78413.
151. Jaafar H., Sharif S.E., Murtey M.D. Pattern of collagen fibers and localization of matrix metalloproteinase 2 and 9 during breast cancer invasion. Tumori 2014, 100:e204-e211.
152. Luo L., Ok Lee S., Liang L., Huang C.K., Li L., Wen S., Chang C. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 2014, 33:2768-2778.
153. Asuthkar S., Velpula K.K., Nalla A.K., Gogineni V.R., Gondi C.S., Rao J.S. Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells. Oncogene 2014, 33:1922-1933.
154. Taguchi A., Kawana K., Tomio K., Yamashita A., Isobe Y., Nagasaka K., Koga K., Inoue T., Nishida H., Kojima S., Adachi K., Matsumoto Y., Arimoto T., Wada-Hiraike O., Oda K., Kang J.X., Arai H., Arita M., Osuga Y., Fujii T. Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo. PLoS ONE 2014, 9:e89605.
155. Lee M.A., Park J.H., Rhyu S.Y., Oh S.T., Kang W.K., Kim H.N. Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer 2014, 14:125.
156. Allen M.D., Thomas G.J., Clark S., Dawoud M.M., Vallath S., Payne S.J., Gomm J.J., Dreger S.A., Dickinson S., Edwards D.R., Pennington C.J., Sestak I., Cuzick J., Marshall J.F., Hart I.R., Jones J.L. Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin. Cancer Res. 2014, 20:344-357.
157. Redzic J.S., Kendrick A.A., Bahmed K., Dahl K.D., Pearson C.G., Robinson W.A., Robinson S.E., Graner M.W., Eisenmesser E.Z. Extracellular vesicles secreted from cancer cell lines stimulate 12secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS ONE 2013, 8:e71225.
158. Wang X., Lee S.O., Xia S., Jiang Q., Luo J., Li L., Yeh S., Chang C. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-beta→MMP-9 signals. Mol. Cancer Ther. 2013, 12:1026-1037.
159. Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., Fein M., Rasch M.G., Tan Y.X., Qiu J., Park J., Sinha P., Bissell M.J., Frengen E., Werb Z., Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.